Roberts Daryl L, Romay Francisco J
MSP Corp., 5910 Rice Creek Parkway, Ste. 300, Shoreview, Minnesota 55126, USA.
J Aerosol Med. 2005 Winter;18(4):396-413. doi: 10.1089/jam.2005.18.396.
Cascade impaction is a standard test method for characterizing the quality of inhalable drug products. The sizes of the nozzles on each stage of the impactor are the critical dimensions for the performance of the impactor. Compendial reference methods call for periodic measurement of the size of the nozzles on each stage, a procedure known as stage mensuration. There is however currently no guidance on acceptable mensuration criteria. We aim to remedy this situation by providing a sound basis for understanding and using mensuration data, be it for acceptance criteria for new impactors or for the setting of mensuration tolerances for in-use impactors. We first show that multi-nozzle impactor stages behave as if all of the nozzles are equal in size to an effective diameter, , that is composed of the area-mean and areamedian diameters, W* and , calculated directly from the individual nozzle diameters for all nozzles on a given stage (equation 1): W= (W*)(2/3) x (W)(1/3) (1). Hence, the effective diameter provides an intuitive and technically sound basis for setting acceptance criteria for new and in-use impactors. We tabulate these criteria for the Mark II eight-stage Andersen cascade impactor and the Next Generation Pharmaceutical Impactor in a manner similar to the tables of critical impactor dimensions published in EP Supplement 5.1 and in USP 28. For two different impactors or for one impactor measured at two different times (e.g., at manufacture and in use), we find that the D50 values of a given stage are related to the effective diameters by D(50,2)/D(50,1)= (W(2)/W(1))(3/2) (2). Using the stage mensuration data for new, as-manufactured NGIs, we compare the D(50 )values of the first 125 as-manufactured NGIs with those of the archivally calibrated NGI. We further establish that the archivally calibrated NGI has D(50) values within 0.3% of an entirely perfect, hypothetical NGI with all nozzles equal to the nominal nozzle diameters. We also apply the equations to a specific mensurated impactor to show that a used impactor with some nozzles outside of the original manufacturing specifications can have the same aerodynamic performance as a new impactor.
级联冲击是表征吸入药物产品质量的标准测试方法。冲击器每个阶段的喷嘴尺寸是冲击器性能的关键尺寸。药典参考方法要求定期测量每个阶段喷嘴的尺寸,这一过程称为阶段测量。然而,目前尚无关于可接受测量标准的指南。我们旨在通过为理解和使用测量数据提供坚实基础来纠正这种情况,无论是用于新冲击器的验收标准还是用于在用冲击器的测量公差设定。我们首先表明,多喷嘴冲击器阶段的行为就好像所有喷嘴的尺寸都等于有效直径(W),该有效直径由面积平均直径和面积中值直径(W^)和(W_m)组成,直接从给定阶段所有喷嘴的单个喷嘴直径计算得出(方程1):(W = (W^)(2/3)×(W_m)(1/3))(1)。因此,有效直径为设定新冲击器和在用冲击器的验收标准提供了直观且技术上合理的基础。我们以类似于欧洲药典增补5.1和美国药典28中公布的关键冲击器尺寸表的方式,列出了Mark II八级安德森级联冲击器和下一代药物冲击器的这些标准。对于两种不同的冲击器或在两个不同时间(例如在制造时和使用中)测量的一个冲击器,我们发现给定阶段的(D50)值与有效直径的关系为(D(50,2)/D(50,1) = (W(2)/W(1))(3/2))(2)。使用新制造的下一代药物冲击器的阶段测量数据,我们将首批125个新制造的下一代药物冲击器的(D(50))值与经档案校准的下一代药物冲击器的(D(50))值进行比较。我们进一步确定,经档案校准的下一代药物冲击器的(D(50))值在一个完全完美的假设冲击器的(0.3%)以内,该假设冲击器的所有喷嘴都等于标称喷嘴直径。我们还将这些方程应用于一个特定测量的冲击器,以表明一些喷嘴超出原始制造规格的在用冲击器可以具有与新冲击器相同的空气动力学性能。